“ RCTs were excluded that were designed to evaluate agents that primarily modify hormonal levels, such aromatase inhibitors AIs, tamoxifen, or raloxifene, but which may have secondary bone effects priligy 60 mg One of the striking and universal characteristics of DDI is the high intersubject variability in magnitude, regardless of whether the study is done in patients or healthy subjects, and regardless of whether the mechanism is pharmacokinetic, pharmacodynamic, or a mixture of the two ”